Carlo H. Maurer

Munich, BY 81675, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation.

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation.

Journal: The oncologist
Published: August 18, 2025

Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time.

Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time.

Journal: JCI insight
Published: May 27, 2025

Development of a translational radiobiology platform using pancreatic cancer patient-derived organoids for personalized radiation oncology.

Development of a translational radiobiology platform using pancreatic cancer patient-derived organoids for personalized radiation oncology.

Journal: Translational oncology
Published: May 25, 2025

Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma.

Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma.

Journal: Nature biomedical engineering
Published: March 01, 2023

Telomere shortening accelerates tumor initiation in the L2-IL1B mouse model of Barrett esophagus and emerges as a possible biomarker.

Telomere shortening accelerates tumor initiation in the L2-IL1B mouse model of Barrett esophagus and emerges as a possible biomarker.

Journal: Oncotarget
Published: October 05, 2021

Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems.

Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems.

Journal: EMBO molecular medicine
Published: July 19, 2021

Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology.

Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology.

Journal: Gastroenterology
Published: December 11, 2019

Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes.

Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes.

Journal: Gut
Published: October 08, 2018

Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma.

Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma.

Journal: Gut
Published: April 19, 2017
Showing 1-9 of 9

Last Updated: 09/26/2026